(d) the method proposed to be adopted by Government to involve the private sector for the purpose?

THE MINISTER OF STATE IN THE MINISTRY OF DEFENCE AND MINISTER OF STATE IN THE MINISTRY OF PARLIAMENTARY AFFAIRS (SHRI MALLIKARJUN): (a) to (d) An Exposition-cum-Seminar was organised jointly by the IAF and the Confederation of Indian Industry (CII) in New Delhi recently to explore the possibilities of indigenisation of items required by the IAF. Representatives of the DRDO, the IAF, the concerned inspection agencies and about 200 persons from private sector participated in the Seminar. The seminar was an exploratory effort. Concrete proposals are yet to emerge.

Price of Ampicilline and its salts

*35. SHRI H. HANUMANTHAPPA:
SHRI RAJNI RANJAN SAHU:

Will the Minister of CHEMICALS AND FERTILIZERS be pleased to state:

(a) when was the last study into the fair price of Ampicilline and its salts, Amoxicillin Cloxacillin Cephalexin held by the BICP;

(b) when was the report on the cost price study of these drug received by the Ministry in each case.

(c) what are the names of drugs for which BICP could not hold any cost price study during the last four years and the reasons of each;

(d) what are the names of drugs for which the Ministry has fixed or reduced prices during year 1994 when and what was earlier and present price of each;

(e) when were the formulation prices based on each drug were notified and what are the details of same; and

(f) whether it is also a fact that most of the prices have not been implemented, if so, the details and action taken?

THE MINISTER OF CHEMICALS AND FERTILIZERS (SHRI RAM LAKHAN SINGH YADAV): (a) & (b) BICP have conducted cost-cum-technical studies in respect of bulk drugs Ampicillin Sodium Sterile, Amoxycillin, Cloxacillin and Cephalexin, The reports of BICP in respect of these bulk drugs were received in June, 1989, November 1994 May 1990 and January, 1989 respectively.

(c) Out of 142 scheduled bulk drugs listed in DPCO, 1987, BICP has conducted cost-cum-technical studies in respect of 93 indigenously produced scheduled bulk drugs. Out of remaining scheduled bulk drugs, 46 bulk drugs are either wholly or substantially imported. Exemption from price control has been granted in respect of bulk drugs Pivodine Iodine and Glipizide on 28.2.1992 and 4.6.1993 respectively upto 31.12.1995 and 31.12.1996 respectively BICP has already initiated the process of cost-cum-technical study in respect of bulk drug Ampicillin Trihydrate.

(d) The prices of indigenously produced scheduled bulk drugs and prices of ceiling packs of formulations based on scheduled bulk drugs are fixed/revised from time to time and which are notified in the Official Gazette, copies of which are availabe in the Parliament Library. In 1994, prices of 71 bulk drugs were notified and out of this in 62 cases the prices were revised and in 9 cases the prices were fixed.

(e) As the number of such formulations is very large, collection and analysis of the voluminous data may not be commensurate with the results likely to be achieved.

(f) No such instance has come to the notice.